Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 15/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601844 | 0.89 | MRGPRX4 (0.41) | MRGPRX4PPARDPPARAHPGDSMN1; SMN2 | |
| SCHEMBL6601379 | 0.89 | MRGPRX4 (0.41) | MRGPRX4PPARDPPARAHPGDSMN1; SMN2 | |
| SCHEMBL6614651 | 0.89 | MRGPRX4 (0.50) | MRGPRX4PPARDPPARA | |
| SCHEMBL6602247 | 0.86 | MRGPRX4 (0.53) | MRGPRX4 | |
| SCHEMBL6603266 | 0.83 | PPARD (0.39) | MRGPRX4PPARDPPARAHPGD | |
| SCHEMBL6603662 | 0.83 | ICMT (0.41) | MRGPRX4HPGDL3MBTL1S1PR4 | |
| SCHEMBL6605085 | 0.80 | MRGPRX4 (0.42) | MRGPRX4PPARDPPARAHPGDSMN1; SMN2 | |
| SCHEMBL6606018 | 0.79 | KDM4E (0.43) | HPGDSMN1; SMN2L3MBTL1S1PR4 | |
| SCHEMBL6603009 | 0.79 | MRGPRX4 (0.40) | MRGPRX4PPARDPPARAHPGDSMN1; SMN2 | |
| SCHEMBL6602423 | 0.79 | MRGPRX4 (0.51) | MRGPRX4PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-1432689-A1 | PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | Bayer Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027074-A1 | PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | MKI67, CDK4, FLT4 | MRGPRX4 2245/4885PPARD 16/4885PPARA 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.